Salix Pharmaceuticals Given Average Recommendation of “Buy” by Analysts (NASDAQ:SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP) has received a consensus recommendation of “Buy” from the seventeen ratings firms that are covering the stock, American Banking and Market News reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $110.85.
A number of analysts have recently weighed in on SLXP shares. Analysts at Sterne Agee raised their price target on shares of Salix Pharmaceuticals from $126.00 to $130.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Salix Pharmaceuticals from $112.00 to $115.00 in a research note on Thursday, May 22nd. They now have a “hold” rating on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Salix Pharmaceuticals in a research note on Thursday, May 15th. They now have a $133.00 price target on the stock.
Shares of Salix Pharmaceuticals (NASDAQ:SLXP) opened at 114.48 on Wednesday. Salix Pharmaceuticals has a 1-year low of $59.50 and a 1-year high of $120.00. The stock’s 50-day moving average is $107.1 and its 200-day moving average is $99.46. The company has a market cap of $7.259 billion and a price-to-earnings ratio of 97.26.
Salix Pharmaceuticals (NASDAQ:SLXP) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.05 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.91 by $0.14. The company had revenue of $384.00 million for the quarter, compared to the consensus estimate of $372.91 million. During the same quarter in the prior year, the company posted $0.63 earnings per share. The company’s quarterly revenue was up 89.7% on a year-over-year basis. On average, analysts predict that Salix Pharmaceuticals will post $6.50 earnings per share for the current fiscal year.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.